SHARE

News Alert: Citius Pharmaceuticals Receives FDA Approval For LYMPHIR™ (Denileukin Diftitox-Cxdl) Immunotherapy For The Treatment Of Adults With Relapsed Or Refractory Cutaneous T-Cell Lymphoma. Click to Read More.

It calls for attention when a company like Cannabis Science Inc (OTCMKTS:CBIS) starts courting industry veterans in unprecedented ways. Legal marijuana industry is rapidly growing in the U.S. and elsewhere, although it is clear that more work needs to be done in the U.S. to lift exiting heavy blanket in the form of federal regulations.

There is one thing that every marijuana company knows all too well – communication is important at this juncture. You need to ensure that existing investors get the most accurate information to keep them in while also keeping prospective investors posted with the information they might want to have to made sound investment decisions. That is all in the reason Cannabis Science Inc (OTCMKTS:CBIS) recently moved to add investor communications veteran Derwin A. Wallace to its team.

Commencing Wall Street coverage

Cannabis Science Inc (OTCMKTS:CBIS) and Wallace signed a one-year deal that will see Wallace taking over the responsibilities of investor relations communications at Cannabis Science. Specifically, Wallace’s prime focus will be on expanding the company’s financial communications with investors of all kinds. That means that Wallace will spearhead expansion and management of Cannabis Science’s financial communications with both institutional and retail investors. Beyond that, the communications veteran will work to commence the overage of the company by Wall Street research analysts.

Win-win situation

There are a whole lot of communications projects that Wallace will have to handle within his one-year deal with Cannabis Science Inc (OTCMKTS:CBIS). The tapping of Wallace is a win-win deal for Cannabis Science and its shareholders. The company will benefit from speeded up program results and also gain from sustainable operational cash flow. Investors will get want they want to know about the company’s projects and financial health, especially from analysts on Wall Street, to ensure that they make the right investment move.

Revenue prediction

Cannabis Science Inc (OTCMKTS:CBIS) hopes to take its revenue from $0.1 million to more than $64 million within the next five years, which is a bold revenue projection considering that the company has not been able to generate any meaningful annual revenue in its nearly six years in business.